<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01206465</url>
  </required_header>
  <id_info>
    <org_study_id>238-10</org_study_id>
    <secondary_id>NCI-2010-02014</secondary_id>
    <nct_id>NCT01206465</nct_id>
  </id_info>
  <brief_title>Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors</brief_title>
  <official_title>A Phase I Clinical Trial of Sequential Pralatrexate Followed by a 48-hour Infusion of 5- Fluorouracil Given Every Other Week in Adult Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Pralatrexate may stop the growth of tumor cells by blocking some of the enzymes
      needed for cell growth. Drugs used in chemotherapy, such as fluorouracil, work in different
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
      dividing. Giving pralatrexate together with fluorouracil may kill more tumor cells.

      PURPOSE: This phase I trial is studying the side effects and best dose of pralatrexate when
      given together with fluorouracil in treating patients with recurrent solid tumors
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the recommended dose of PDX (pralatrexate) given in combination with a fixed
      dose of 5-FU (fluorouracil) administered as a 48-hour infusion given every other week.

      SECONDARY OBJECTIVES:

      I. To assess clinical response to therapy in subjects with measurable disease and time to
      disease progression in all subjects.

      II. To assess the toxicity profile of the combination of PDX and 5-FU. III. To determine the
      pharmacokinetics of PDX and 5-FU and correlate with clinical toxicity.

      IV. To analyze polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase
      (TS) and correlate with clinical toxicity.

      OUTLINE: This is a dose-escalation study of pralatrexate.

      Patients receive pralatrexate intravenously (IV) over 5 minutes on day 1 and fluorouracil IV
      continuously over 48 hours on days 2 and 16. Courses repeat every 28 days in the absence of
      disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up for 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">February 4, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended Dose of PDX Given in Combination With a Fixed Dose of 5-FU Administered as a 48-hour Infusion Given Every Other Week</measure>
    <time_frame>During the initial course (day 1 &amp; 15 of a 4 week schedule)</time_frame>
    <description>Maximum tolerated dose will have been exceeded when 2 patients entered at a given dose level experience specified dose-limiting toxicities in the initial cycle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Response to Therapy in Subjects With Measurable Disease</measure>
    <time_frame>restaging imaging done after each two 4-week course until time of progression (the maximum duration of PFS = 588 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Experiencing Grade 3-4 Toxicity While Receiving the Combination of PDX and 5-FU</measure>
    <time_frame>., &quot;From the time the subject signs the consent form and ending 4 weeks following the final chemotherapy, an average of 3 years</time_frame>
    <description>patients remained on study as long as they did not progress, and wished to continue on study (no limit on number of cycles)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of PDX- AUClast</measure>
    <time_frame>Pre-treatment, end of infusion, at 15, 30, and 60 min, and then at 2, 4, 6, 8, 12, 22, 23, 24, 45, and 46 hours for PDX.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Polymorphisms in Methylenetetrahydrofolate Reductase and Thymidylate Synthase</measure>
    <time_frame>Prior to the first dose of protocol therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of 5-FU - Cmax Plasma Levels</measure>
    <time_frame>22, 23, 45 &amp; 46 hours during the 48 hour infusion</time_frame>
    <description>5-FU plasma levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Disease Progression in All Participants</measure>
    <time_frame>restaging imaging done after each two 4-week course until time of progression (longest time to progression = 588 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive pralatrexate IV over 5 minutes on day 1 and fluorouracil IV continuously over 48 hours on days 2 and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pralatrexate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
    <other_name>FOLOTYN</other_name>
    <other_name>PDX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
    <other_name>5-fluorouracil</other_name>
    <other_name>5-Fluracil</other_name>
    <other_name>5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>high performance liquid chromatography</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
    <other_name>HPLC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
    <other_name>PCR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>nucleic acid sequencing</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
    <other_name>Gene Sequencing</other_name>
    <other_name>Molecular Biology, Nucleic Acid Sequencing</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacogenomic studies</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
    <other_name>Pharmacogenomic Study</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymorphism analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cancer patients who have failed standard therapy for their disease or for whom no such
             therapy is available are eligible, for which 5-fluoropyrimdines, including 5-FU, or
             inhibitors of DHFR (dihydrofolate reductase), including pralatrexate, have the
             potential for therapeutic benefit

          -  Objectively measurable disease is preferred, but not required

          -  Performance status of 0-2 (Eastern Cooperative Oncology Group [ECOG])

          -  Prior treatment:

          -  The patient should have recovered from the toxicities associated with prior
             chemotherapy (at least 3 weeks from prior therapy)

          -  At least two or more weeks should have elapsed since any radiotherapy, and the patient
             should have recovered from the toxicity associated with such therapy

          -  If a recent surgical procedure has been performed, the patient should have recovered
             from the surgery prior to entering this trial

          -  Absolute granulocyte count of 1500 per mcL or greater

          -  Platelet count of 100,000 per mcL or greater

          -  Serum bilirubin less than 1.5 times the upper limits of the institutional normal

          -  Serum creatinine less than the upper limits of normal

          -  The patient must willingly give signed informed consent

        Exclusion Criteria:

          -  Pregnant women and nursing mothers are ineligible; eligible patients of reproductive
             potential should use adequate contraception if sexually active

          -  Serious concurrent medical illness which would jeopardize the ability of the patient
             to receive the chemotherapy program outlined in this protocol with reasonable safety

          -  Patients with active infections requiring intravenous antibiotic therapy are not
             eligible until the infection has resolved

          -  Patients who are human immunodeficiency virus (HIV) antibody positive and are
             receiving highly active antiretroviral therapy (HAART) are ineligible

          -  Concomitant administration of nonsteroidal anti-inflammatory drugs (NSAIDs) and
             trimethoprim/sulfamethoxazole will not be allowed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Grem</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UNMC Eppley Cancer Center at the University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-6805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Grem JL, Kos ME, Evande RE, Meza JL, Schwarz JK. A phase 1 clinical trial of sequential pralatrexate followed by a 48-hour infusion of 5-fluorouracil given every other week in adult patients with solid tumors. Cancer. 2015 Nov 1;121(21):3862-8. doi: 10.1002/cncr.29504. Epub 2015 Aug 4.</citation>
    <PMID>26242208</PMID>
  </results_reference>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>September 17, 2010</study_first_submitted>
  <study_first_submitted_qc>September 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2010</study_first_posted>
  <results_first_submitted>February 4, 2018</results_first_submitted>
  <results_first_submitted_qc>July 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 16, 2018</results_first_posted>
  <last_update_submitted>July 13, 2018</last_update_submitted>
  <last_update_submitted_qc>July 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Jean Grem, MD</investigator_full_name>
    <investigator_title>Primary Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>29 signed a consent form. Two patients never received any study drug: one became ineligible due to rise in bilirubin; another decided against participating.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>75 mg/m^2</title>
          <description>pralatrexate (PDX) dose level</description>
        </group>
        <group group_id="P2">
          <title>94 mg/m^2</title>
          <description>pralatrexate (PDX) dose level</description>
        </group>
        <group group_id="P3">
          <title>118 mg/m^2</title>
          <description>pralatrexate (PDX) dose level</description>
        </group>
        <group group_id="P4">
          <title>148 mg/m^2</title>
          <description>pralatrexate (PDX) dose level</description>
        </group>
        <group group_id="P5">
          <title>185 mg/m^2</title>
          <description>pralatrexate (PDX) dose level</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis was performed on 27 patients who received study drug; 2 patients did not receive any study drug (1 changed mind after signing consent; 1 no longer eligible due to elevated bilirubin)</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Enzyme Inhibitor Therapy)</title>
          <description>Patients receive pralatrexate IV over 5 minutes on day 1 and fluorouracil IV continuously over 48 hours on days 2 and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="30" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race/Ethnicity</title>
              <category_list>
                <category>
                  <title>Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black, not of hispanic origin</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Recommended Dose of PDX Given in Combination With a Fixed Dose of 5-FU Administered as a 48-hour Infusion Given Every Other Week</title>
        <description>Maximum tolerated dose will have been exceeded when 2 patients entered at a given dose level experience specified dose-limiting toxicities in the initial cycle</description>
        <time_frame>During the initial course (day 1 &amp; 15 of a 4 week schedule)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Enzyme Inhibitor Therapy)</title>
            <description>Patients receive pralatrexate IV over 5 minutes on day 1 and fluorouracil IV continuously over 48 hours on days 2 and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Recommended Dose of PDX Given in Combination With a Fixed Dose of 5-FU Administered as a 48-hour Infusion Given Every Other Week</title>
          <description>Maximum tolerated dose will have been exceeded when 2 patients entered at a given dose level experience specified dose-limiting toxicities in the initial cycle</description>
          <units>mg per meter square</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Response to Therapy in Subjects With Measurable Disease</title>
        <time_frame>restaging imaging done after each two 4-week course until time of progression (the maximum duration of PFS = 588 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Enzyme Inhibitor Therapy)</title>
            <description>Patients receive pralatrexate IV over 5 minutes on day 1 and fluorouracil IV continuously over 48 hours on days 2 and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Response to Therapy in Subjects With Measurable Disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>complete or partial response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>stable disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>progressive disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Experiencing Grade 3-4 Toxicity While Receiving the Combination of PDX and 5-FU</title>
        <description>patients remained on study as long as they did not progress, and wished to continue on study (no limit on number of cycles)</description>
        <time_frame>., &quot;From the time the subject signs the consent form and ending 4 weeks following the final chemotherapy, an average of 3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Enzyme Inhibitor Therapy)</title>
            <description>Patients receive pralatrexate IV over 5 minutes on day 1 and fluorouracil IV continuously over 48 hours on days 2 and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Experiencing Grade 3-4 Toxicity While Receiving the Combination of PDX and 5-FU</title>
          <description>patients remained on study as long as they did not progress, and wished to continue on study (no limit on number of cycles)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>gr 3-4 neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>gr 3-4 thrombocytopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>gr 3-4 anemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>gr 3-4 diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>gr 3-4 mucositis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>gr 3-4 dehydration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>gr 3-4 fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of PDX- AUClast</title>
        <time_frame>Pre-treatment, end of infusion, at 15, 30, and 60 min, and then at 2, 4, 6, 8, 12, 22, 23, 24, 45, and 46 hours for PDX.</time_frame>
        <population>AUClast</population>
        <group_list>
          <group group_id="O1">
            <title>75 mg/m^2</title>
            <description>pralatrexate (PDX) Dose level 1</description>
          </group>
          <group group_id="O2">
            <title>94 mg/m^2</title>
            <description>PDX Dose Level 2</description>
          </group>
          <group group_id="O3">
            <title>118 mg/m^2</title>
            <description>PDX Dose level 3</description>
          </group>
          <group group_id="O4">
            <title>148 mg/m^2</title>
            <description>PDX Dose level 4</description>
          </group>
          <group group_id="O5">
            <title>185 mg/m^2</title>
            <description>PDX Dose level 5</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of PDX- AUClast</title>
          <population>AUClast</population>
          <units>ng/ml *hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12,818" spread="578"/>
                    <measurement group_id="O2" value="16300" spread="728"/>
                    <measurement group_id="O3" value="15680" spread="801"/>
                    <measurement group_id="O4" value="23570" spread="2411"/>
                    <measurement group_id="O5" value="42121" spread="1051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Polymorphisms in Methylenetetrahydrofolate Reductase and Thymidylate Synthase</title>
        <time_frame>Prior to the first dose of protocol therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Wild Type</title>
          </group>
          <group group_id="O2">
            <title>Heterozygous</title>
          </group>
          <group group_id="O3">
            <title>Homozygous Variant</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Polymorphisms in Methylenetetrahydrofolate Reductase and Thymidylate Synthase</title>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SLC19A1 80G&gt;A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.9"/>
                    <measurement group_id="O2" value="40.7"/>
                    <measurement group_id="O3" value="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>gamma glutamyl hydrolase (GGH) 401C&gt;T</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6"/>
                    <measurement group_id="O2" value="37.0"/>
                    <measurement group_id="O3" value="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>gamma glutamyl hydrolase (GGH) 452C&gt;T</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9"/>
                    <measurement group_id="O2" value="11.1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>folyl polyglutamate synthase (FPGS) rs10760502A&gt;G</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0"/>
                    <measurement group_id="O2" value="4.0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>folyl polyglutamate synthase (FPGS) rs1544105C&gt;T</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.9"/>
                    <measurement group_id="O2" value="55.6"/>
                    <measurement group_id="O3" value="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>methylene tetrahydrofolate reductase (MTHFR 677C&gt;T</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6"/>
                    <measurement group_id="O2" value="25.9"/>
                    <measurement group_id="O3" value="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>methylene tetrahydrofolate reductase MTHFR 1298A&gt;C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.9"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>thymidylate synthase 28-bp tandem repeats (2 or 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8"/>
                    <measurement group_id="O2" value="48.2"/>
                    <measurement group_id="O3" value="37.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of 5-FU - Cmax Plasma Levels</title>
        <description>5-FU plasma levels</description>
        <time_frame>22, 23, 45 &amp; 46 hours during the 48 hour infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>22 Hours</title>
            <description>5 FU plasma levels</description>
          </group>
          <group group_id="O2">
            <title>23 Hours</title>
            <description>5 FU plasma levels</description>
          </group>
          <group group_id="O3">
            <title>45 Hours</title>
            <description>5 FU plasma levels</description>
          </group>
          <group group_id="O4">
            <title>46 Hours</title>
            <description>5 FU plasma levels</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of 5-FU - Cmax Plasma Levels</title>
          <description>5-FU plasma levels</description>
          <units>mg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1147" spread="133"/>
                    <measurement group_id="O2" value="1159" spread="121"/>
                    <measurement group_id="O3" value="1123" spread="130"/>
                    <measurement group_id="O4" value="1113" spread="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Disease Progression in All Participants</title>
        <time_frame>restaging imaging done after each two 4-week course until time of progression (longest time to progression = 588 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Enzyme Inhibitor Therapy)</title>
            <description>Patients receive pralatrexate IV over 5 minutes on day 1 and fluorouracil IV continuously over 48 hours on days 2 and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Disease Progression in All Participants</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112" lower_limit="28" upper_limit="588"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data is collected on participants from the time of consent until 30 days after the participant is off study drug.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Enzyme Inhibitor Therapy)</title>
          <description>Patients receive pralatrexate IV over 5 minutes on day 1 and fluorouracil IV continuously over 48 hours on days 2 and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal disorders - Other</sub_title>
                <description>diverticulitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Infection and infestations- Other</sub_title>
                <description>related to mucositis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Joint infection</sub_title>
                <description>knee</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <description>tibia bone</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <description>surgery</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders- Other</sub_title>
                <description>mental status change</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic Event</sub_title>
                <description>Pulmonary emboli</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Localized Edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>white blood cell decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobinuria</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash, maculo-papular</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jean L. Grem,MD</name_or_title>
      <organization>University of Nebraska Medical Center</organization>
      <phone>402-559-5166</phone>
      <email>jgrem@unmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

